Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques

免疫接种可扩增小鼠和猕猴体内针对 HIV-1 V3 聚糖的特异性 B 细胞。

阅读:2
作者:Amelia Escolano ,Harry B Gristick ,Morgan E Abernathy ,Julia Merkenschlager ,Rajeev Gautam ,Thiago Y Oliveira ,Joy Pai ,Anthony P West Jr ,Christopher O Barnes ,Alexander A Cohen ,Haoqing Wang ,Jovana Golijanin ,Daniel Yost ,Jennifer R Keeffe ,Zijun Wang ,Peng Zhao ,Kai-Hui Yao ,Jens Bauer ,Lilian Nogueira ,Han Gao ,Alisa V Voll ,David C Montefiori ,Michael S Seaman ,Anna Gazumyan ,Murillo Silva ,Andrew T McGuire ,Leonidas Stamatatos ,Darrell J Irvine ,Lance Wells ,Malcolm A Martin ,Pamela J Bjorkman ,Michel C Nussenzweig

Abstract

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans. However, it has not yet been possible to induce adequate serological responses by vaccination. Here, to activate B cells that express precursors of broadly neutralizing antibodies within polyclonal repertoires, we developed an immunogen, RC1, that facilitates the recognition of the variable loop 3 (V3)-glycan patch on the envelope protein of HIV-1. RC1 conceals non-conserved immunodominant regions by the addition of glycans and/or multimerization on virus-like particles. Immunization of mice, rabbits and rhesus macaques with RC1 elicited serological responses that targeted the V3-glycan patch. Antibody cloning and cryo-electron microscopy structures of antibody-envelope complexes confirmed that immunization with RC1 expands clones of B cells that carry the anti-V3-glycan patch antibodies, which resemble precursors of human broadly neutralizing antibodies. Thus, RC1 may be a suitable priming immunogen for sequential vaccination strategies in the context of polyclonal repertoires.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。